Psilocybin for Trauma-Related Disorders
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An open-label study in traumatized AIDS survivors found that PAP reduced PTSD symptoms, attachment anxiety, and demoralization. Several PAP trials show preliminary efficacy in facilitating confronting traumatic memories, decreasing emotional avoidance, depression, anxiety, pessimism, and disconnection from others, and increasing acceptance, self-compassion, and forgiveness of abusers, all of which are relevant to PTSD recovery. There is also early evidence that other classic psychedelics may produce large reductions in PTSD symptoms in combat veterans. However, this body of literature is small, mechanisms are not yet well understood, and the risks of using psychedelic compounds for trauma-related disorders need further study. In sum, evidence supports further investigation of PAP as a radically new approach for treating PTSD. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Herzog R, Mediano PAM, Rosas FE et al (2020) A mechanistic model of the neural entropy increase elicited by psychedelic drugs. Sci Rep 10:17725”
Cited work 10.1038/s41598-020-74060-6 · retracted 2022-09-15 · notice 10.1038/s41598-022-20093-y · this paper published 2022
Citations
Cites
1 retracted
RETRACTED ARTICLE: A mechanistic model of the neural entropy increase elicited by psychedelic drugs
Herzog, R., Mediano, P. A. M., Rosas, F. E., Carhart-Harris, R., Perl, Y. S., Tagliazucchi, E., & Cofre, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74060-6 · Cited by 49
RetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Emotional processing of fear: Exposure to corrective information.
Foa, E. B., & Kozak, M. J. (1986) · Psychological Bulletin · doi:10.1037/0033-2909.99.1.20 · Cited by 5,396
Moral injury and moral repair in war veterans: A preliminary model and intervention strategy
Litz, B. T., Stein, N., Delaney, E., Lebowitz, L., Nash, W. P., Silva, C., & Maguen, S. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.07.003 · Cited by 2,738
Trauma and PTSD in the WHO World Mental Health Surveys
Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Benjet, C., Bromet, E. J., Cardoso, G., Degenhardt, L., de Girolamo, G., Dinolova, R. V., Ferry, F., et al. (2017) · European Journal of Psychotraumatology · doi:10.1080/20008198.2017.1353383 · Cited by 1,661
Cloitre, M., Stolbach, B. C., Herman, J. L., Kolk, B. V. D., Pynoos, R., Wang, J., & Petkova, E. (2009) · Journal of Traumatic Stress · doi:10.1002/jts.20444 · Cited by 1,473
Benjet, C., Bromet, E., Karam, E. G., Kessler, R. C., McLaughlin, K. A., Ruscio, A. M., Shahly, V., Stein, D. J., Petukhova, M., Hill, E., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715001981 · Cited by 1,458
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Sexual abuse and lifetime diagnosis of psychiatric disorders: Systematic review and meta-analysis
Chen, L. P., Murad, M. H., Paras, M. L., Colbenson, K. M., Sattler, A. L., Goranson, E. N., Elamin, M. B., Seime, R. J., Shinozaki, G., Prokop, L. J., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0583 · Cited by 1,056
Research works printed but not linked: 1
- Wasson RG (1980) The wondrous mushroom. Mycolatry in Mesoamerica. Ethnomycoloical studies no. 7. McGraw-Hill Book Company, New York
Cited by
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity
Du, Y., Li, Y., Zhao, X., Yao, Y., Wang, B., Zhang, L., & Wang, G. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002647 · Cited by 94
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 102
Kopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 68
Sabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 71
“Signi fi cant breakthroughs in psychedelic research provide valuable insights into the mechanisms of mental disorders and offer novel therapeutic strategies for treatment-resistant conditions in depression [2], substance use disorders [3], anxiety [4], and post-traumatic stress disorder (PTSD) [5].”
Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors
Woodburn, S. C., Levitt, C. M., Koester, A., & Kwan, A. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00279 · Cited by 58
Update on treatments for anxiety-related disorders
Lee, H. J., & Stein, M. B. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000841 · Cited by 43
“The mushroom extract, psilocybin, has historically been a psychedelic agent for religious and spiritual ceremonies and a therapeutic option for neuropsychiatric conditions [18].”
Background(2022) · Current topics in behavioral neurosciences · doi:10.1007/978-3-031-12184-5 · Cited by 27
Kinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 18
Trauma under psychedelics: how psychoactive substances impact trauma processing
Netzer, O., Magal, N., Stern, Y., Polinsky, T., Gross, R., Admon, R., & Salomon, R. (2025) · World Psychiatry · doi:10.1002/wps.21363 · Cited by 20
Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
Fonseka, L. N., & Woo, B. K. P. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i5.182 · Cited by 15
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
Rosal, S. P., Torre, J. T. L., Birnkammer, S., Chernoloz, O., Williams, M. T., & Faber, S. C. (2024) · BMC Medical Education · doi:10.1186/s12909-024-06141-3 · Cited by 16
“Beyond MDMA, other psychedelics, such as psilocy-bin, have shown promise in the treatment of PTSD. Early phase trials and case studies suggest that psilocybin, when combined with psychotherapeutic support, may significantly reduce PTSD symptoms [58].”
BackgroundThe effect of low-dose psilocybin on brain neurotransmission and rat behavior
Bysiek, A., Wojtas, A., Szpręgiel, I., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111347 · Cited by 15
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
Psilocybin-assisted therapy and HIV-related shame
Mehtani, N. J., Johnson, M. O., Hendricks, P. S., Mitchell, J., & Anderson, B. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-68908-4 · Cited by 10
Kinderlehrer, D. A. (2023) · International Medical Case Reports Journal · doi:10.2147/imcrj.s395342 · Cited by 13
Guo, C., Luu, N. N. T., Adwer, M. M., Hosseinzadeh, H., Balan, V., Yan, Y., & Lin, Y. (2025) · Metabolic Engineering · doi:10.1016/j.ymben.2025.11.002 · Cited by 12
Trauma and Remembering: From Neuronal Circuits to Molecules
Kéri, S. (2022) · Life · doi:10.3390/life12111707 · Cited by 9
Koweszko, T., de Barbaro, B., Izydorczyk, B., Mastalerz–Migas, A., Samochowiec, J., Szulc, A., Kowalska, A., Wachowska, K., & Gałecki, P. (2023) · Psychiatria Polska · doi:10.12740/pp/166172 · Cited by 7
“Psychedelic therapy is based on psychotherapy supported by the use of these psychoactive substances [68].”
BackgroundJasemi, E., Razmi, A., Vaseghi, S., Amiri, S., & Najafi, S. M. A. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000813 · Cited by 7
“Also, P. cubensis may be beneficial in the treatment of post-traumatic stress disorder (PTSD) (Khan et al ., 2022) and obsessive-compulsive disorder (Moreno et al ., 2006; Wilcox, 2014).”
Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy
Khan, F. A., Pandupuspitasari, N. S., Tencomnao, T., & Chuchawankul, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120882 · Cited by 8
Blest‐Hopley, G., Pasculli, G., Ruffell, S., Tsang, W., Olateju, E., Pate, K. M., Kettner, H., Roseman, L., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1594307 · Cited by 8
“Mental health and wellbeing will be measured by a battery of behavioural questionnaires, that assess symptoms of PTSD, depression, anxiety, sleep, concussion related symptoms, wellbeing, quality of life and military to civilian connectedness.”
InfluentialModlin, N. L., Williamson, V., Maggio, C., Stubley, J., Kirlić, N., Cleare, A. J., & Rucker, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251342319 · Cited by 3
Brudner, R. M., Kaczmarek, E. S., Blainey, M. G., Schulz-Quach, C., Meshkat, S., Doyle, Z., Lipsitz, O., Offman, H., Sethi, R., Weiglein, G., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251346697 · Cited by 11
O’Regan, G., Plummer, Z., Christie, B. R., Shultz, S. R., & Allen, J. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03717-2 · Cited by 15
Blanton, A. M., Parikh, P., Zhou, S., Mohamed, M., Ufret-Vincenty, R. L., & Mancini, R. (2025) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2025.102359 · Cited by 7
Christen, S. E., Bekka, E., Schmid, Y., Benowitz, N. L., & Liakoni, E. (2025) · Swiss Medical Weekly · doi:10.57187/s.4346 · Cited by 4
A narrative exploration of psilocybin’s potential in mental health
Min, H., Park, S.-Y., Park, J., Na, S., Lee, H.-S., Kim, T., Ham, J., & Park, Y.-T. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1429373 · Cited by 7
The future of psychiatry: clinical practice, diagnosis, and treatment
Turner, S., Yadav, P., Morrin, H., & Bhat, A. (2025) · International Review of Psychiatry · doi:10.1080/09540261.2025.2594523 · Cited by 23
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
“30,33,62 The current landscape of pharmacological treatments for PTSD While current treatment guidelines promote psy-chotherapies as the gold-standard interventions for PTSD, some pharmacological interventions are also supported for their relative strength of literature evidence and greater…”
Tunstad, P. A., Kvam, T.-M., Uthaug, M. V., Stewart, L. H., Andersen, K. A. A., & Grønnerød, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1556299 · Cited by 4
“We are not aware of any published studies on psilocybin or psilocybin-assisted psychotherapy as treatment for post-traumatic stress disorder (PTSD), however there is ongoing research actively exploring its potential (Choi et al., 2024; Khan et al., 2022).”
Schuler, H., Zhou, D., Savignac, C., Cvetkovska, V., Tse, Y.-C., Meccia, J., Lopez, J., Harutyunyan, A. S., Ragoussis, J., Bzdok, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.08.631940 · Cited by 5
Effects of Psilocybin on Mouse Brain Microstructure
Frautschi, P. C., Singh, A. P., Stowe, N. A., Grady, S. M., Zahid, Z., Banks, M. I., & Yu, J. J. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8634 · Cited by 2
Beesley, V. L., Kennedy, T., Maccallum, F., Ross, M., Harvey, R., Rossell, S. L., Sarris, J. J., Perkins, D., Neale, R. Ε., Bennett–Levy, J., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095992 · Cited by 4
Psychedelics - A Cure for Sexual Trauma or a Risk Factor in Recreational and Treatment Settings?
Struble, C. A. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00372-x · Cited by 2
Brown, R., Hamilton, N. M., Mallon, C., Stevenson, J., Faley, M. T., Kargbo, R. B., Sherwood, A. M., & Upeandran, B. (2025) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4155 · Cited by 1
He, Z., Wang, Y., Chen, J., Cheng, J., Feng, Y., Niu, S., & Yan, J. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02165-y · Cited by 1
Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats
Bysiek, A., Szpręgiel, I., Wojtas, A., Maćkowiak, M., Wawrzczak‐Bargieła, A., Leśkiewicz, M., Trojan, E., Kamińska, K., Kumorek, W., Bilecki, W., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111710 · Cited by 1
Robinson, J., Wallace, N., Cassidy, E. K., Lake, S., & Lucas, P. (2026) · Contemporary Drug Problems · doi:10.1177/00914509261444382 · Cited by 1
Allen, J., Jupp, B., Baker, T. L., Haskali, M. B., Brkljača, R., Plummer, Z., Sun, M., Brand, J., Christie, B. R., Debert, C. T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102867 · Cited by 2
“Psilocybin, a potent 5-HT 2A agonist, shows promise in treating complex neuropsychiatric conditions like depression, anxiety, and post-traumatic stress disorder, 16–23 which share key patho-physiological features with TBI, including impaired neuroplasticity, neuroinflammation, and neurotransmission.”
Neurociência do canabidiol – aspectos neurocognitivos, terapêuticos e comportamentais
Barbosa, F. C., Tadine, R. M., Rezende, J. D. P., Lopes, G. C. D., & Shiozawa, P. (2023) · OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA · doi:10.55905/oelv21n8-058
Wąsik, K., Tomaszuk, S., & Wojtuś, M. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.50.01.005
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00010-7
Uma breve história dos combatentes movidos a drogas
Davidson, C. (2024) · doi:10.64628/ade.jeak7whfe
Meijer, T. L., van Opdorp, A., & Markus, W. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100014
The impact of a combatant's social and employment status on combat stress experiences
Hryn, K. V. (2025) · Ukrainian Journal of Occupational Health · doi:10.33573/ujoh2025.04.309
Cullen, J. (2026) · Person-Centered & Experiential Psychotherapies · doi:10.1080/14779757.2026.2651879
Rodriguez, J., Duquesne-Maldonado, Y., Hernández-Torres, J. M., Sant’Ana, I. D. L., & Nazario, C. M. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00519
Hajivalizadeh, S., Farahmand, K., Kazemzadeh, K., Hajivalizadeh, G., & Shamabadi, A. (2026) · Cancer Reports · doi:10.1002/cnr2.70587
Tabaac, B. J., Carhart-Harris, R. L., & Yung, T. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1840956 · Cited by 2
“While this is a single case series of the patients demonstrating profound benefit, the work contributes to a growing body of research exploring alternative therapeutic approaches for TBI (Brody and Siddiqi, 2024; Cherian K. N. et al., 2024; Khan et al., 2022).”
Du, Y. J., Zhao, X., Yao, Y., Li, Y., Wang, G., & Zhang, L. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453819
Haggarty, C. J., & Rabinak, C. A. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02502-2
“Although trauma-focused psy-chotherapies and fi rst-line pharmacotherapies (e.g., SSRIs) are effective for many individuals, a substantial proportion remains symptomatic, motivating interest in novel pharmacologic approaches and drug-assisted psychotherapy [3 – 7].”
Recent Advances in Engineering Microbial Cell Factories for Tryptophan-Derived Chemicals
Qiu, C., Guo, H., Ren, Q., Sun, Y., Qu, G., Wang, Y., Zheng, M., & Sun, Z. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c04381
Du, Y., Zhao, X., Chen, Q., Bai, Y., Zhang, Y., Chen, R., & Wang, G. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004350
Metadata
- Authors
- Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Woolley, Joshua
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer International Publishing
- Published
- 2022
- Volume
- 56
- Pages
- 319-332
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W4283070601
- Cited by
- 67
- References
- 88
- Citations by year
- 2026: 16 · 2025: 25 · 2024: 15 · 2023: 8 · 2022: 3
- FWCI
- 99.93
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- psilocybin, post-traumatic stress disorder, psilocybin-assisted therapy, psychedelic therapy, trauma, combat veterans, attachment anxiety, demoralization, emotional avoidance, self-compassion, forgiveness, classic psychedelics
- MeSH terms
- Hallucinogens, Humans, Psilocybin, Psychotherapy, Stress Disorders, Post-Traumatic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.